Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deoxyribonuclease in Oshadi carrier
- Development stage
- Phase 2
- Lead developer
- Oshadi Drug Administration
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
Oshadi D is an investigational anticancer drug delivery system developed by Oshadi Drug Administration. It utilizes a proprietary oral, controlled-release nanoparticle formulation to deliver deoxyribonuclease (DNase) enzymes. The mechanism of action involves the enzymatic breakdown of extracellular DNA, which can accumulate in the tumor microenvironment and contribute to cancer progression and metastasis. By degrading this extracellular DNA, DNase may reduce tumor growth and enhance the efficacy of chemotherapy. Preclinical studies and early-phase clinical trials have evaluated its safety and antitumor activity, particularly in combination with other agents such as docetaxel or salvage chemotherapy for cancers including metastatic mesothelioma, non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and basal cell carcinoma[1][2][3][4]. The drug has shown a good safety profile with no dose-limiting toxicities observed in early studies.
- Other names
- DNase in Oshadi carrier
02
Targets
eDNA (Extracellular DNA)
Beyond the preview
Go deeper on Deoxyribonuclease in Oshadi carrier.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deoxyribonuclease in Oshadi carrier.